<DOC>
	<DOCNO>NCT00226447</DOCNO>
	<brief_summary>The aim investigate best treatment regime PEG-Intron A lamivudine combination term viral clearance chronic hepatitis B patient .</brief_summary>
	<brief_title>Different Regimens Pegylated Interferon Lamivudine Combination Therapy Chronic Hepatitis B Patients</brief_title>
	<detailed_description>Chronic hepatitis B major cause mortality morbidity Hong Kong Southeast Asian country . The efficacy interferon-alfa ( IFN-alfa ) lamivudine monotherapy far satisfactory approximately 20 % sustained viral response . Extended use lamivudine associate emergence drug resistance mutant . As interferon immune modulator lamivudine directly suppress viral replication , therefore logical combine 2 drug efficient viral clearance . Previous study IFN-alfa lamivudine combination treatment chronic hepatitis B show marginal benefit lamivudine monotherapy . In study , lamivudine either start 8 week prior IFN-alfa simultaneous IFN-alfa . Recently , perform study compare efficacy polyethylene glycol-interferon alfa-2b ( PEG-Intron A ) lamivudine versus lamivudine monotherapy 1 year treatment chronic hepatitis B . In protocol , PEG-Intron A start 8 week commencement lamivudine , PEG-Intron A give 32 week lamivudine give total 52 week . Our published result suggest PEG-Intron A lamivudine combination treatment far superior lamivudine monotherapy ( end treatment virological response 92 % vs 20 % , p=0.0015 ) . We certain whether benefit PEG-Intron A lamivudine combination study due stagger regime , superiority PEG-Intron A IFN-alfa , . The aim study investigate best treatment regime PEG-Intron A lamivudine combination term viral clearance .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBsAg positive least 6 month prior screen Serum HBVDNA &gt; 10^6 copy per ml screen Serum HBeAg positive screening Abnormal ALT ( 1.310x upper limit normal ) within one month prior entry Compensated liver disease follow minimum criterion : 1 . Hemoglobin within range &amp; less 10 % low normal limit 2 . WBC &gt; = 4,000/mm3 3 . Platelets &gt; = 100,000/mm3 4 . Bilirubin normal ( except Gilbert 's disease ) . 5 . Albumin stable normal Serum creatinine normal 10 % upper normal limit Thyroid Stimulating Hormone ( TSH ) within normal limit ( Patients require medication maintain TSH level normal range eligible inclusion/exclusion criterion meet . ) Alfafetoprotein normal range ( obtain within previous year , elevate &lt; 500 ng/ml negative ultrasound hepatocellular carcinoma screen ) . Written inform consent Coinfection hepatitis C virus and/or HIV Evidence history decompensated liver disease 1 . Child 's B cirrhosis 2 . Ascites , bleed varix , spontaneous encephalopathy 3 . Hypersplenism ( hemoglobin , white cell count , platelet outside inclusion criterion ) 4 . Coagulopathy ( PT &gt; 13 sec ) Any know preexist medical condition could interfere patient 's participation completion treatment : Preexisting psychiatric condition , especially severe depression , history severe psychiatric disorder . Patients antidepressant therapy exclude CNS trauma active seizure disorder require medication Poorly control diabetes mellitus Immunologically mediate disease ( e.g. , inflammatory bowel disease ( Crohn 's disease , ulcerative colitis , idiopathic thrombocytopenic purpura , lupus erythematous , autoimmune hemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis ) . Clinical gout ANA &gt; 1:320 documentation woman childbearing potential use contraception . A serum pregnancy test obtain within two week prior initiation treatment must negative . Female patient must breast feeding . Any known history hypersensitivity nucleoside analogues interferon Previous use interferon , lamivudine , immunosuppressive drug corticosteroid Subjects clinically significant retinal abnormality Substance abuse , alcohol ( &gt; 80 g/day ) , iv drug inhale drug . If subject history substance abuse , consider inclusion protocol , subject must abstain use abused substance least 2 year . Subjects receive methadone within past 2 year also exclude . Subjects willing counseled/abstain consumption alcohol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>Lamivudine</keyword>
</DOC>